$PVCT Up to date company activities and other impo
Post# of 89397
Posted On: 06/12/2014 10:04:21 AM
$PVCT Up to date company activities and other important information about $PVCT
$PVCT
DD Notes ~ http://www.ddnotesmaker.com/PVCT
##### recent news/filings ~ source: finance.yahoo.com
Thu, 12 Jun 2014 10:10:00 GMT ~ 6:10 am Provectus Pharma to discuss outline of Phase 3 clinical trial of PV-10 to treat melanoma on conference call on June 19, 2014, at 4 pm ET
read full: http://finance.yahoo.com/news/inplay-briefing....html#pvct
*********************************************************
Thu, 12 Jun 2014 10:04:25 GMT ~ PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disc
read full: http://biz.yahoo.com/e/140612/pvct8-k.html
*********************************************************
Thu, 12 Jun 2014 10:00:00 GMT ~ Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call
- Provectus Biopharmaceuticals, Inc. , , a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold
read full: http://finance.yahoo.com/news/provectus-bioph...00932.html
*********************************************************
Fri, 06 Jun 2014 23:00:00 GMT ~ Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Securities Class Action Against Provectus Biopharmaceuticals, Inc. Has Been Filed in the United States District Court for the Middle District of Tennessee
- NEW YORK -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit against Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT) ("Provectus" or the "Company"
...
read full: http://finance.yahoo.com/news/wolf-haldenstei...00118.html
*********************************************************
Fri, 06 Jun 2014 19:10:00 GMT ~ SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Provectus Biopharmaceuticals, Inc. To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit
- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Provectus Biopharmaceuticals, Inc.
read full: http://finance.yahoo.com/news/shareholder-ale...00573.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=PVCT&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=PVCT&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PVCT/company-info
Ticker: $PVCT
OTC Market Place: Not Available
CIK code: 0000315545
Company name: Provectus Biopharmaceuticals, Inc.
Company website: http://www.pvct.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/PVCT/filings
Latest financials: http://www.otcmarkets.com/stock/PVCT/financials
Latest news: http://www.otcmarkets.com/stock/PVCT/news - http://finance.yahoo.com/q/h?s=PVCT+Headlines
Major holdings: http://data.cnbc.com/quotes/PVCT/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=PVCT+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/PVCT.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=PVCT
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Provectus+Biopharm...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.pvct.com
Alexa: http://www.alexa.com/siteinfo/http://www.pvct.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.pvct.com
Short Sales: http://www.otcmarkets.com/stock/PVCT/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/PVCT/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/PVCT/research
Historical Prices: http://finance.yahoo.com/q/hp?s=PVCT+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=PVCT+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=PVCT+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=PVCT+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=PVCT+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=PVCT+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=PVCT
Balance Sheet: http://finance.yahoo.com/q/bs?s=PVCT
Cash Flow: http://finance.yahoo.com/q/cf?s=PVCT+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/PVCT
Bloomberg: http://www.bloomberg.com/quote/PVCT:US
Morningstar: http://quotes.morningstar.com/stock/s?t=PVCT
Bussinessweek: http://investing.businessweek.com/research/st...icker=PVCT
Barchart: http://www.barchart.com/quotes/stocks/PVCT
OTC Short Report: http://otcshortreport.com/index.php?index=PVCT
Investopedia: http://www.investopedia.com/markets/stocks/PVCT/?wa=0
http://www.pennystocktweets.com/stocks/profile/PVCT
##### last known share structure ~ source: otcmarkets.com
Market Value: $212,944,946 a/o Jun 11, 2014
Shares Outstanding: 173,125,972 a/o Mar 31, 2014
Float: 95,000,000 a/o Jul 15, 2013
Authorized Shares: 250,000,000 a/o Jul 15, 2013
Par Value: 0.001
##### business description ~ source: otcmarkets.com
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.Less >>
DD Notes ~ http://www.ddnotesmaker.com/PVCT
$PVCT
DD Notes ~ http://www.ddnotesmaker.com/PVCT
##### recent news/filings ~ source: finance.yahoo.com
Thu, 12 Jun 2014 10:10:00 GMT ~ 6:10 am Provectus Pharma to discuss outline of Phase 3 clinical trial of PV-10 to treat melanoma on conference call on June 19, 2014, at 4 pm ET
read full: http://finance.yahoo.com/news/inplay-briefing....html#pvct
*********************************************************
Thu, 12 Jun 2014 10:04:25 GMT ~ PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disc
read full: http://biz.yahoo.com/e/140612/pvct8-k.html
*********************************************************
Thu, 12 Jun 2014 10:00:00 GMT ~ Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call
- Provectus Biopharmaceuticals, Inc. , , a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold
read full: http://finance.yahoo.com/news/provectus-bioph...00932.html
*********************************************************
Fri, 06 Jun 2014 23:00:00 GMT ~ Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Securities Class Action Against Provectus Biopharmaceuticals, Inc. Has Been Filed in the United States District Court for the Middle District of Tennessee
- NEW YORK -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit against Provectus Biopharmaceuticals, Inc. (NYSE MKT
VCT) ("Provectus" or the "Company" ... read full: http://finance.yahoo.com/news/wolf-haldenstei...00118.html
*********************************************************
Fri, 06 Jun 2014 19:10:00 GMT ~ SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Provectus Biopharmaceuticals, Inc. To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit
- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Provectus Biopharmaceuticals, Inc.
read full: http://finance.yahoo.com/news/shareholder-ale...00573.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=PVCT&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=PVCT&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PVCT/company-info
Ticker: $PVCT
OTC Market Place: Not Available
CIK code: 0000315545
Company name: Provectus Biopharmaceuticals, Inc.
Company website: http://www.pvct.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/PVCT/filings
Latest financials: http://www.otcmarkets.com/stock/PVCT/financials
Latest news: http://www.otcmarkets.com/stock/PVCT/news - http://finance.yahoo.com/q/h?s=PVCT+Headlines
Major holdings: http://data.cnbc.com/quotes/PVCT/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=PVCT+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/PVCT.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=PVCT
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Provectus+Biopharm...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.pvct.com
Alexa: http://www.alexa.com/siteinfo/http://www.pvct.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.pvct.com
Short Sales: http://www.otcmarkets.com/stock/PVCT/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/PVCT/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/PVCT/research
Historical Prices: http://finance.yahoo.com/q/hp?s=PVCT+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=PVCT+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=PVCT+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=PVCT+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=PVCT+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=PVCT+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=PVCT
Balance Sheet: http://finance.yahoo.com/q/bs?s=PVCT
Cash Flow: http://finance.yahoo.com/q/cf?s=PVCT+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/PVCT
Bloomberg: http://www.bloomberg.com/quote/PVCT:US
Morningstar: http://quotes.morningstar.com/stock/s?t=PVCT
Bussinessweek: http://investing.businessweek.com/research/st...icker=PVCT
Barchart: http://www.barchart.com/quotes/stocks/PVCT
OTC Short Report: http://otcshortreport.com/index.php?index=PVCT
Investopedia: http://www.investopedia.com/markets/stocks/PVCT/?wa=0
http://www.pennystocktweets.com/stocks/profile/PVCT
##### last known share structure ~ source: otcmarkets.com
Market Value: $212,944,946 a/o Jun 11, 2014
Shares Outstanding: 173,125,972 a/o Mar 31, 2014
Float: 95,000,000 a/o Jul 15, 2013
Authorized Shares: 250,000,000 a/o Jul 15, 2013
Par Value: 0.001
##### business description ~ source: otcmarkets.com
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.Less >>
DD Notes ~ http://www.ddnotesmaker.com/PVCT
(0)
(0)